Effects of bisphosphonates in children with osteogenesis imperfecta: An AACPDM systematic review

Developmental Medicine and Child Neurology

Volumn 51, Issue 1, 2009, Pages 17-29

  Castillo, Heidi ^a   Samson Fang, Lisa ^b,c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN TYPE 7; COLLAGEN TYPE 8; ETIDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PROCOLLAGEN; RISEDRONIC ACID; ZOLEDRONIC ACID;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE PHASE RESPONSE; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE GROWTH; BONE MALFORMATION; BONE PAIN; BONE REMODELING; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FEVER; FLU LIKE SYNDROME; FRACTURE; FRACTURE NONUNION; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL DISEASE; GENE MUTATION; HEADACHE; HEALTH CARE ORGANIZATION; HUMAN; HYPERTHERMIA; HYPOCALCEMIA; INTERNAL VALIDITY; LIMB PAIN; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL RESEARCH; MYALGIA; NAUSEA; ORTHOPEDIC SURGERY; OSSIFICATION; OSTEOGENESIS IMPERFECTA; OUTCOME ASSESSMENT; PAIN; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; REVIEW; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; TACHYCARDIA; TASTE DISORDER; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNITED STATES; UREA NITROGEN BLOOD LEVEL; VOMITING; WOUND HEALING IMPAIRMENT;

BODY HEIGHT; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; DIPHOSPHONATES; EVIDENCE-BASED MEDICINE; FRACTURES, SPONTANEOUS; HUMANS; LONG-TERM CARE; OSTEOGENESIS IMPERFECTA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 57949110203     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/j.1469-8749.2008.03222.x     Document Type: Review

References (86)

1. Plotkin H. Syndromes with congenital brittle bones. BMC Pediatrics 2004; 4: 16.
2. Lindsay R. Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest 2002; 110: 1239-41.
3. Sillence DO, Senn AS, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Gen 1979; 16: 101-16.
4. Byers PH. Osteogenesis imperfecta: Perspectives and opportunities. Pediatrics 2000; 12: 603-09.
5. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97: 1227-31.
6. Albright JA. Systemic treatment of osteogenesis imperfecta. Clin Orthop Relat Res 1981; 159: 88-96.
7. Devogelaer JP, Malghem J, Maldague B, Nagat de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987; 16: 360-63.
8. American Academy of Cerebral Palsy and Developmental Medicine. AACPDM methodology for developing evidence tables and reviewing treatment outcome research. Revision 1.1. http://www.aacpdm.org/resources/ systematicReviewsMethodology.pdf (accessed 16 July 2008).
9. International Classification of Functioning, Disability and Health (ICF). Geneva: World Health Organization, 2001.
10. Phillips R, Ball C, Sackett D, et al. Oxford Centre for Evidence-Based Medicine levels of evidence, May 2001. http://www.cebm.net/index.aspx?o= 1047 (accessed 16 July 2008).
11. Sakkers R, Kok D, Engelbert R, et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: A 2 year randomised placebo-controlled study. Lancet 2004; 363: 1427-31.
12. Gatti D, Antoniazzi F, Prizzi R, et al. Intravenous neridronate in children with osteogenesis imperfecta: A randomized controlled study. J Bone Miner Res 2005; 20: 758-63.
13. Letocha AD, Cintas HL, Troendle JF, et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20: 977-86.
14. Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25: 786-91.
15. Antoniazzi F, Zamboni G, Lauriola S, Donaldi L, Adami S, Tato L. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta. J Pediatr 2006; 149: 174-79.
16. Rauch F, Munns CFJ, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: Effect of treatment discontinuation. J Clin Endocrinol Metab 2006; 91: 1268-74.
17. DiMeglio LA, Ford L, McClintock C, Peacock M. A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2005; 18: 43-53.
18. DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 132-40.
19. Bishop NJ, Lanoue G, Chabot G, Travers R, Glorieux FH. Clinical and bone densitometric improvement after pamidronate infusion in children with severe osteogenesis imperfecta. Presented at the American Society for Bone and Mineral Research 18th Annual Meeting, Seattle, WA, USA, 1996.
20. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr 1997; 131: 622-25.
21. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr 1998; 157: 261-62.
22. Shaw NJ. Bisphosphonates in osteogenesis imperfecta. Arch Dis Child 1997; 77: 92-93.
23. Astrom E, Soderhall S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998; 87: 64-68.
24. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-52.
25. Kodama H, Kubota K, Abe T. Osteogenesis imperfecta: Are fractures and growth hormone treatment linked. J Pediatr 1998; 123: 559-60.
26. Plotkin H, Rauch F, Bishop MJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846-50.
27. Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2001; 14: 529-33.
28. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralization and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001; 160: 641-44.
29. Banerjee I, Shortland GJ, Evans WD, Gregory JW. Osteogenesis imperfecta and intravenous pamidronate. Arch Dis Child 2002; 87: 562-63.
30. Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110: 1293-99.
31. Chien YH, Chu SY, Hsu CC, Hwu WL. Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant. J Inherit Metab Dis 2002; 25: 593-95.
32. Falk MJ, Heeger S, Lynch KA, et al. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003; 111: 573-78.
33. Grissom LE, Harcke HT. Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003; 33: 226-29.
34. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH. Osteogenesis imperfecta types I, III, and IV: Effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003; 88: 986-92.
35. Adiyaman P, Ocal G, Berberoglu M, Evliyaoglu ZA, Chabot G. The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta. Turk J Pediatr 2004; 46: 322-28.
36. Arikoski P, Silverwood B, Tillman V, Bishop NJ. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004; 34: 539-46.
37. Bin-Abbas BS, Al-Ashwal AA, Al-Zayed ZS, Sakati NA. Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta. Saudi Med J 2004; 25: 1772-73.
38. DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004; 35: 1038-45.
39. Munns CFJ, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004; 35: 231-34.
40. Munns CFJ, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004; 19: 1779-86.
41. Zacharin M, Kanumakala S. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. J Pediatr Endocrinol Metab 2004; 17: 1511-17.
42. Cho TJ, Choi IH, Chung CY, Yoo WJ, Park MS, Park YK. Efficacy of oral alendronate in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25: 607-12.
43. Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C. Benefits of pamidronate in children with osteogenesis imperfecta: An open prospective study. Joint Bone Spine 2005; 72: 313-18.
44. Munns CFJ, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome. J Bone Miner Res 2005; 20: 1235-43.
45. Pizones J, Plotkin H, Parra-Garcia JI, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop 2005; 25: 332-35.
46. Ward LM, Denker AE, Porras A, et al. Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I. J Clin Endocrinol Metab 2005; 90: 4051-56.
47. El Sobky MA, Hanna AAZ, Basha NE, Tarraf YN, Said MH. Surgery versus surgery plus pamidronate in the management of osteogenesis imperfecta patients: A comparative study. J Pediatr Orthop B 2007; 15: 222-28.
48. Goksen D, Coker M, Darcan S, Kose T, Kara S. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta. Turk J Pediatr 2007; 48: 124-29.
49. Land C, Rauch F, Glorieux FH. Cyclic intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 374-79.
50. Vallo A, Rodriguez-Leyva F, Rodriguez-Soriano J. Osteogenesis imperfecta: Anthropometric, skeletal, and mineral metabolic effects of long-term intravenous pamidronate therapy. Acta Paediatr 2006; 95: 332-39.
51. Zeitlin L, Rimorac D, Travers R, Munns CFJ, Glorieux FH. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Type V. Bone 2006; 38: 13-20.
52. Astrom E, Jorulf H, Soderhall S. Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta. Arch Dis Child 2007; 92: 332-38.
53. Choi JH, Shin YL, Yoo HW. Short-term efficacy of monthly pamidronate infusions in patients with osteogenesis imperfecta. J Korean Med Sci 2007; 22: 209-12.
54. Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: Effects of cyclical intravenous pamidronate treatment. Bone 2007; 40: 638-44.
55. Burke TE, Crerand SJ, Dowling F. Hypertrophic callus formation leading to high-output cardiac failure in a patient with osteogenesis imperfecta. J Pediatr Orthop 1988; 8: 605-08.
56. Huaux JP, Lokietek W. Is APD a promising drug in the treatment of severe osteogenesis imperfecta. J Pediatr Orthop 1988; 8: 71-72.
57. Devogelaer JP, Nagat de Deuxchaisnes C, Malghem J, Maldague B. Cyclical intermittent therapy with APD in child with osteogenesis imperfecta: A 3 year follow-up of 7 cycles. Evidence of fading away of the oldest radio-opaque metaphyseal bands. In:
58. Christiansen C, Overgaard K, eds. Osteoporosis. Aalborg: Handelstrykkeriet Aalborg ApS, 1990: 1515-17.
59. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine (Baltimore) 1997; 76: 266-83.
60. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr 1997; 156: 792-94.
61. Williams CJ, Smith RA, Ball RJ, Wilkinson H. Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. Arch Dis Child 1997; 76: 169-70.
62. Roldan EJ, Pasqualini T, Plantalech L. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients. J Pediatr Endocrinol Metab 1999; 12: 555-59.
63. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86: 562-63.
64. Ashford RU, Dey A, Kayan K, McCloskey EV, Kanis JA. Oral clodronate as treatment of osteogenesis imperfecta. Arch Dis Child 2003; 88: 945 [Letter].
65. Davies JH, Gregory JW. Radiologic long bone appearance in a child administered cyclical pamidronate. Arch Dis Child 2003; 88: 854. [Letter]
66. Maasalu K, Haviko T, Marston A. Treatment of children with osteogenesis imperfecta in Estonia. Acta Paediatr 2003; 92: 452-55.
67. Montpetit K, Plotkin H, Rauch F, et al. Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. Pediatrics 2003; 111: E601-03.
68. Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size and density in children and adolescents with osteogenesis imperfecta: Effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18: 610-14.
69. Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003; 111: 1030-36.
70. Rauch F, Travers R, Munns CFJ, Glorieux FH. Sclerotic metaphyseal lines in a child treated with pamidronate: Histomorphometric analysis. J Bone Miner Res 2004; 19: 1191-93.
71. Fleming F, Woodhead HF, Briody JN, et al. Cyclic bisphosphonate therapy in osteogenesis imperfecta type V. J Paediatr Child Health 2005; 41: 147-51.
72. Unal E, Abaci A, Bober E, Buyukgebiz A. Oral alendronate in osteogenesis imperfecta. Indian Pediatr 2005; 42: 1158-60.
73. Vyskocil V, Pikner R, Kutilek S. Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 2005; 72: 416-23.
74. Land C, Rauch F, Munns CFJ, Sahebjam S, Glorieux FH. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006; 39: 901-06.
75. Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006; 148: 456-60.
76. Lee DY, Cho TJ, Choi IH, et al. Clinical and radiological manifestations of osteogenesis imperfecta type V. J Korean Med Sci 2006; 21: 709-14.
77. Madenci E, Yilmaz K, Yilmaz M, Coskun Y. Alendronate treatment in osteogenesis imperfecta. J Clin Rheumatol 2006; 12: 53-56.
78. Pan CH, Ma SC, Wu CT, Chen PQ. A pedicle screw fixation technique in correcting severe kyphoscoliosis in an osteogenesis imperfecta patient. J Spinal Disord Tech 2006; 19: 368-72.
79. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: Histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006; 91: 511-16.
80. Weber M, Roschger P, Fratzl-Zelman N, et al. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta. Bone 2006; 39: 616-22.
81. Rauch F, Cornibert S, Cheung M, Glorieux FH. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 2007; 40: 821-27.
82. Marini JC. Do bisphosphonates make children's bones better or brittle. N Engl J Med 2003; 31: 423-26.
83. Papapoulos SE, Cremers SCLM. Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007; 356: 1075-76.
84. Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 2006; 22: 578-79.
85. Munns CFJ, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: A report of two cases. J Bone Miner Res 2004; 19: 1742-45.
86. Cabar FR, Nomura RM, Zugaib M. Maternal and fetal outcome of pamidronate treatment before conception: A case report. Clin Exp Rheumatol 2007; 25: 344-45.